Reuters logo
BRIEF-Fate Therapeutics says investigational new drug application for its cancer drug gets FDA clearance
March 13, 2017 / 12:18 PM / 6 months ago

BRIEF-Fate Therapeutics says investigational new drug application for its cancer drug gets FDA clearance

March 13 (Reuters) - Fate Therapeutics Inc-

* Fate Therapeutics announces FDA clearance of investigational new drug application for FATE-NK100 natural killer cell cancer immunotherapy

* Fate Therapeutics -expects a first-in-human clinical trial of fate-nk100 for aml to open enrollment at masonic cancer center, university of Minnesota Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below